LONP1 Double Nickase Plasmid (h): sc-411273-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LONP1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LONP1 Double Nickase Plasmid (h) and LONP1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LONP1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LONP1 Antibody (3B2): sc-293244
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LONP1 Double Nickase Plasmid (h) | sc-411273-NIC | 20 µg | $410.00 |
LONP1 encodes a mitochondrial matrix ATP-dependent protease (LonP1) that maintains proteostasis by recognizing, unfolding, and degrading misfolded or oxidatively damaged proteins. It supports mitochondrial quality control, mtDNA maintenance, and the mitochondrial unfolded protein response, thereby influencing oxidative phosphorylation efficiency, ROS handling, and stress-adaptive signaling. LONP1 function intersects with mitochondrial biogenesis and mitophagy-related processes that preserve organelle integrity under metabolic or proteotoxic stress. Dysregulated LONP1 activity has been associated with mitochondrial dysfunction phenotypes and is studied in contexts of neurodegeneration, cardiometabolic stress, and tumor cell adaptation to altered bioenergetics.
LONP1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LONP1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LONP1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LONP1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LONP1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.